Working Paper Article Version 1 This version is not peer-reviewed

Virtual Screening of Approved Clinic Drugs with Main Protease (3CLpro) Reveals Potential Inhibitory Effects on SARS-CoV-2

Version 1 : Received: 7 March 2020 / Approved: 8 March 2020 / Online: 8 March 2020 (17:14:57 CET)

How to cite: Wang, Q.; Zhao, Y.; Chen, X.; Hong, A. Virtual Screening of Approved Clinic Drugs with Main Protease (3CLpro) Reveals Potential Inhibitory Effects on SARS-CoV-2. Preprints 2020, 2020030144 Wang, Q.; Zhao, Y.; Chen, X.; Hong, A. Virtual Screening of Approved Clinic Drugs with Main Protease (3CLpro) Reveals Potential Inhibitory Effects on SARS-CoV-2. Preprints 2020, 2020030144

Abstract

3CLpro is the main protease of the novel coronavirus (SARS-CoV-2) responsible for their intracellular duplication. Based on virtual screening technology, we found 23 approved clinical drugs such as Carfilzomib, Saquinavir, Thymopentin and etc., which showed high affinity with the 3CLpro active sites. These findings suggest that 3CLpro inhibitors might be potential candidates for further activity detection and molecular modification.

Subject Areas

SARS-CoV-2; 3CLpro; approved drugs; virtual screening

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.